{"id":11009,"date":"2024-06-10T12:55:00","date_gmt":"2024-06-10T10:55:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=11009"},"modified":"2025-08-07T13:01:23","modified_gmt":"2025-08-07T11:01:23","slug":"therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/","title":{"rendered":"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Rolf Bambauer\u00b9*, Ralf Schiel\u00b2, Octavio J Salgado\u00b3and Richard Straube (2024) Adv Res Dermatol Cosmetics 3: 1017<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Severe and\/or refractory dermatological diseases with immunologic origin to conventional therapy have a bad<br>prognosis. Autoimmune blistering diseases have a high morbidity and mortality. Therapeutic apheresis is an essential supportive treatment for severe and refractory dermatological diseases with an immunologic origin, particularly autoimmune blistering diseases. This approach has been shown to significantly improve the prognosis of these diseases.<br>Therapeutic apheresis, combined with immunosuppressive therapy and\/or human monoclonal antibodies, has treated successfully autoimmune blistering skin disorders. These diseases are caused by the immune system\u2019s targeting of structural proteins in the skin and\/or mucous membranes. Improved diagnostic methods have allowed to determine that the incidence and prevalence of these disorders have doubled in the last 15 years to 25 new cases per million people per year owing to an aging population. Over the last 45 years, therapeutic apheresis, in combination with immunosuppression and\/or human monoclonal antibodies, has significantly increased survival rates. Therapeutic apheresis using hollow fiber modules is safe and highly effective in eliminating autoantibodies and other toxins from the bloodstream, leading to rapid clinical improvement in dermatological conditions. The guidelines of the for American Application Committee of the American Society for Apheresis are cited dermatologic disorders, which could be treated with therapeutic apheresis<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Rolf Bambauer\u00b9*, Ralf Schiel\u00b2, Octavio J Salgado\u00b3and Richard Straube (2024) Adv Res Dermatol Cosmetics 3: 1017 Severe and\/or refractory dermatological diseases with immunologic origin to conventional therapy have a badprognosis. Autoimmune blistering diseases have a high morbidity and mortality. Therapeutic apheresis is an essential supportive treatment for severe and refractory dermatological diseases with an immunologic [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[203,196,115,362],"class_list":["post-11009","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-behcets-disease","scientific_tags-psoriasis","scientific_tags-pyoderma-gangrenosum","scientific_tags-therapeutic-apheresis"],"acf":{"sc_authors":"https:\/\/www.poli-praxis.info\/wp-content\/uploads\/2025\/05\/ARDC-V3-24-117-1-24.pdf\r\n\r\n&nbsp;"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Rolf Bambauer\u00b9*, Ralf Schiel\u00b2, Octavio J Salgado\u00b3and Richard Straube (2024) Adv Res Dermatol Cosmetics 3: 1017 Severe and\/or refractory dermatological diseases with immunologic origin to conventional therapy have a badprognosis. Autoimmune blistering diseases have a high morbidity and mortality. Therapeutic apheresis is an essential supportive treatment for severe and refractory dermatological diseases with an immunologic [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T11:01:23+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/\",\"name\":\"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2024-06-10T10:55:00+00:00\",\"dateModified\":\"2025-08-07T11:01:23+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/","og_locale":"fr_FR","og_type":"article","og_title":"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte","og_description":"Rolf Bambauer\u00b9*, Ralf Schiel\u00b2, Octavio J Salgado\u00b3and Richard Straube (2024) Adv Res Dermatol Cosmetics 3: 1017 Severe and\/or refractory dermatological diseases with immunologic origin to conventional therapy have a badprognosis. Autoimmune blistering diseases have a high morbidity and mortality. Therapeutic apheresis is an essential supportive treatment for severe and refractory dermatological diseases with an immunologic [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/","og_site_name":"Adacyte","article_modified_time":"2025-08-07T11:01:23+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/","name":"Therapeutic Apheresis,Immunosuppression, and HumanMonoclonal Antibodies inDermatologic Diseases - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2024-06-10T10:55:00+00:00","dateModified":"2025-08-07T11:01:23+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeutic-apheresisimmunosuppression-and-humanmonoclonal-antibodies-indermatologic-diseases\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/11009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=11009"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=11009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}